Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GCK | P35557 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 4/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | IL2 | P60568 | 3/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12848888 | 0.85 | LMNA (0.43) | LMNAGSK3BDYRK1AABCB1CYP11B1 | |
| SCHEMBL12848953 | 0.84 | ADORA2B (0.44) | LMNAGSK3BDYRK1AABL1ABCB1 | |
| SCHEMBL12796670 | 0.83 | ABCB1 (0.42) | GCKDYRK1AABCB1CYP11B1CYP11B2 | |
| SCHEMBL12848829 | 0.82 | LMNA (0.49) | LMNAGSK3BDYRK1AABL1ABCB1 | |
| SCHEMBL12796628 | 0.80 | LMNA (0.44) | LMNADYRK1AABCB1CYP11B1CYP11B2 | |
| SCHEMBL449982 | 0.77 | IL2 (0.63) | LMNAABL1ABCB1IL2DEGS1 | |
| SCHEMBL439102 | 0.77 | ABCB1 (0.49) | LMNADYRK1AABCB1ALDH1A1IL2 | |
| SCHEMBL12848831 | 0.77 | DYRK1A (0.46) | LMNAGSK3BDYRK1AABL1ABCB1 | |
| SCHEMBL11911923 | 0.75 | IL2 (0.65) | LMNAIL2 | |
| SCHEMBL12796659 | 0.75 | ABCB1 (0.46) | ABL1ABCB1CYP11B1CYP11B2DEGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110052643-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2011-03-03 | — | — | US | disclosed |
| WO-2009089305-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110052643-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | TSLP, NFATC1, IL5 | LMNA 4871/4885GCK 1648/4885GSK3B 1985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.